|
1
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sathornsumetee S, Reardon DA, Desjardins
A, Quinn JA, Vredenburgh JJ and Rich JN: Molecularly targeted
therapy for malignant glioma. Cancer. 110:13–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Davis ME: Glioblastoma: Overview of
disease and treatment. Clin J Oncol Nurs. 20 (5 Suppl):S2–S8. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ostrom QT, Bauchet L, Davis FG, Deltour I,
Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh
KM, et al: The epidemiology of glioma in adults: A ‘state of the
science’ review. Neuro Oncol. 16:896–913. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Morgan MA and Canman CE: Replication
stress: An achilles' heel of glioma cancer stem-like cells. Cancer
Res. 78:6713–6716. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weller M, van den Bent M, Tonn JC, Stupp
R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Rhun EL,
Balana C, Chinot O, et al: European association for neuro-oncology
(EANO) guideline on the diagnosis and treatment of adult astrocytic
and oligodendroglial gliomas. Lancet Oncol. 18:e315–e329. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nilsson P, Gedda L, Sjöström A and
Carlsson J: Effects of dextranation on the uptake of peptides in
micrometastases: Studies on binding of EGF in tumor spheroids.
Tumour Biol. 22:229–238. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thuringer D, Hammann A, Benikhlef N,
Fourmaux E, Bouchot A, Wettstein G, Solary E and Garrido C:
Transactivation of the epidermal growth factor receptor by heat
shock protein 90 via Toll-like receptor 4 contributes to the
migration of glioblastoma cells. J Biol Chem. 286:3418–3428. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
O-charoenrat P, Rhys-Evans P, Court WJ,
Box GM and Eccles SA: Differential modulation of proliferation,
matrix metalloproteinase expression and invasion of human head and
neck squamous carcinoma cells by c-ErbB ligands. Clin Exp
Metastasis. 17:631–639. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Forster JA, Paul AB, Harnden P and Knowles
MA: Expression of NRG1 and its receptors in human bladder cancer.
Br J Cancer. 104:1135–1143. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheng H, Terai M, Kageyama K, Ozaki S,
McCue PA, Sato T and Aplin AE: Paracrine effect of NRG1 and HGF
drives resistance to MEK inhibitors in metastatic uveal melanoma.
Cancer Res. 75:2737–2748. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Buonanno A and Fischbach GD: Neuregulin
and ErbB receptor signaling pathways in the nervous system. Curr
Opin Neurobiol. 11:287–296. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ritch PS, Carroll SL and Sontheimer H:
Neuregulin-1 enhances survival of human astrocytic glioma cells.
Glia. 51:217–228. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Senchenko VN, Krasnov GS, Dmitriev AA,
Kudryavtseva AV, Anedchenko EA, Braga EA, Pronina IV, Kondratieva
TT, Ivanov SV, Zabarovsky ER and Lerman MI: Differential expression
of CHL1 gene during development of major human cancers. PLoS One.
6:e156122011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schmid RS and Maness PF: L1 and NCAM
adhesion molecules as signaling coreceptors in neuronal migration
and process outgrowth. Curr Opin Neurobiol. 18:245–250. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Panicker AK, Buhusi M, Thelen K and Maness
PF: Cellular signalling mechanisms of neural cell adhesion
molecules. Front Biosci. 8:d900–d911. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sasaki H, Yoshida K, Ikeda E, Asou H,
Inaba M, Otani M and Kawase T: Expression of the neural cell
adhesion molecule in astrocytic tumors: An inverse correlation with
malignancy. Cancer. 82:1921–1931. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Long MJ, Wu FX, Li P, Liu M, Li X and Tang
H: MicroRNA-10a targets CHL1 and promotes cell growth, migration
and invasion in human cervical cancer cells. Cancer Lett.
324:186–196. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Y, Yu Y, Schachner M and Zhao W:
Neuregulin 1-β regulates cell adhesion molecule L1 expression in
the cortex and hippocampus of mice. Biochem Biophys Res Commun.
441:7–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao WJ and Schachner M: Neuregulin 1
enhances cell adhesion molecule l1 expression in human glioma cells
and promotes their migration as a function of malignancy. J
Neuropathol Exp Neurol. 72:244–255. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella- Branger D, Cavenee WK, Ohgaki H, Wiestler
OD, Kleihues P and Ellison DW: The 2016 world health organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ritch PA, Carroll SL and Sontheimer H:
Neuregulin-1 enhances motility and migration of human astrocytic
glioma cells. J Biol Chem. 278:20971–20978. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Demyanenko GP, Schachner M, Anton E,
Schmid R, Feng G, Sanes J and Maness PF: Close homolog of L1
modulates area-specific neuronal positioning and dendrite
orientation in the cerebral cortex. Neuron. 44:423–437. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sytnyk V, Leshchyns'ka I and Schachner M:
Neural cell adhesion molecules of the immunoglobulin superfamily
regulate synapse formation, maintenance, and function. Trends
Neurosci. 40:295–308. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He LH, Ma Q, Shi YH, Ge J, Zhao HM, Li SF
and Tong ZS: CHL1 is involved in human breast tumorigenesis and
progression. Biochem Biophys Res Commun. 438:433–438. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang Z, Xie Q, Hu CL, Jiang Q, Shen HF,
Schachner M and Zhao WJ: CHL1 is expressed and functions as a
malignancy promoter in glioma cells. Front Mol Neurosci.
10:3242017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fan HC, Chen CM, Chi CS, Tsai JD, Chiang
KL, Chang YK, Lin SZ and Harn HJ: Targeting telomerase and
ATRX/DAXX inducing tumor senescence and apoptosis in the malignant
glioma. Int J Mol Sci. 20(pii): E2002019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Debacq-Chainiaux F, Erusalimsky JD,
Campisi J and Toussaint O: Protocols to detect
senescence-associated beta-galactosidase (SA-beta gal) activity, a
biomarker of senescent cells in culture and in vivo. Nat Protoc.
4:1798–1806. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Alver TN, Lavelle TJ, Longva AS, Øy GF,
Hovig E and Bøe SL: MITF depletion elevates expression levels of
ERBB3 receptor and its cognate ligand NRG1-beta in melanoma.
Oncotarget. 7:55128–55140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Asati V, Mahapatra DK and Bharti SK:
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as
anticancer agents: Structural and pharmacological perspectives. Eur
J Med Chem. 109:314–341. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao HF, Wang J, Shao W, Wu CP, Chen ZP,
To ST and Li WP: Recent advances in the use of PI3K inhibitors for
glioblastoma multiforme: Current preclinical and clinical
development. Mol Cancer. 16:1002017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li X, Wu C, Chen N, Gu H, Yen A, Cao L,
Wang E and Wang L: PI3K/Akt/mTOR signaling pathway and targeted
therapy for glioblastoma. Oncotarget. 7:33440–33450.
2016.PubMed/NCBI
|
|
36
|
Rodon J, Dienstmann R, Serra V and
Tabernero J: Development of PI3K inhibitors: Lessons learned from
early clinical trials. Nat Rev Clin Oncol. 10:143–153. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yin F, Zhang JN, Wang SW, Zhou CH, Zhao
MM, Fan WH, Fan M and Liu S: MiR-125a-3p regulates glioma apoptosis
and invasion by regulating Nrg1. PLoS One. 10:e01167592015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li Y, Li Y, Ge P and Ma C: MiR-126
regulates the ERK pathway via targeting KRAS to inhibit the glioma
cell proliferation and invasion. Mol Neurobiol. 54:137–145. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li B, Wang F, Liu N, Shen W and Huang T:
Astragaloside IV inhibits progression of glioma via blocking
MAPK/ERK signaling pathway. Biochem Biophys Res Commun. 491:98–103.
2017. View Article : Google Scholar : PubMed/NCBI
|
